Efficacy and Safety of SPARC0921 in Subjects With Spasticity

Trial Profile

Efficacy and Safety of SPARC0921 in Subjects With Spasticity

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 11 Oct 2017

At a glance

  • Drugs Baclofen (Primary)
  • Indications Multiple sclerosis; Muscle spasticity
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Sun Pharma Advanced Research Company
  • Most Recent Events

    • 11 Oct 2017 This trial has been completed in Hungary, according to European Clinical Trials Database
    • 24 May 2017 Planned End Date changed from 1 Jan 2018 to 1 Aug 2017.
    • 24 May 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Aug 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top